Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease

CSF and plasma exposures reinforce VTX3232’s potential as a once-daily oral therapy for neurodegenerative diseases

Read more at globenewswire.com